– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib...
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across...
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1,...
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered...
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of...
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host...
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring...
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger,...
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability...
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2026,...